News In Brief From Elcelyx, Medivir, Repligen
Elcelyx spins out new company to advance weight-loss supplement while it focuses on delayed-release metformin for type 2 diabetes. Also, Medivir announces promising data for a combination of HCV drugs in patients with advanced fibrosis or cirrhosis of the liver, while Repligen has earned its first milestone under a collaboration in spinal muscular atrophy with Pfizer.
You may also be interested in...
Spinal muscular atrophy is a rare disease that affects a small patient population of children. Isis is ready to move its compound into mid-stage testing after positive Phase I results, but the biotech isn’t the only company exploring the field.
Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.
It's not clear that the proposed revisions and additions to the Centers for Medicare and Medicaid Services’ existing coverage with evidence development study design requirements would address what some experts view as a program failure – the fact that sponsors of the vast majority of technologies subject to CED have not generated the data CMS is looking for.